Home
Conditions
Paraproteinemias

Clinical trial condition

Paraproteinemias

Explore clinical trials studying Paraproteinemias. Study availability and eligibility vary by location and protocol.

3,002 public trials 569 recruiting studies

Refine in advanced search Browse all conditions

Paraproteinemias trial results

Active, Not Recruiting

A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis

NCT06649695

Conditions: AL Amyloidosis, Amyloidosis, Immune System Diseases, +10 more
Locations: South Australia Health Adelaide, Australia

Westmead Hospital Sydney, Australia

CHU Limoges Limoges, France

University Hospital Essen Essen, Germany

View Trial Details

Active, Not Recruiting

CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

NCT03798678

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: Yale University New Haven, Connecticut, United States

Moffitt Cancer Center Tampa, Florida, United States

Mayo Clinic in Rochester Rochester, Minnesota, United States

Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States

View Trial Details

Active, Not Recruiting

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

NCT06390826

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

NCT06385483

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

NCT07085728

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: Alaska Oncology and Hematology LLC Anchorage, Alaska, United States

View Trial Details

Active, Not Recruiting

Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma

NCT02603887

Conditions: Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, Not Recruiting

Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

NCT04439318

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +22 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

NCT04439357

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +22 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Elimination of Minimal Residual Disease After Transplant

NCT05690984

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +16 more
Locations: Froedtert Hospital & the Medical College of Wisconsin Milwaukee, Wisconsin, United States

View Trial Details

Active, Not Recruiting

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

NCT03896737

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Disease, +15 more
Locations: Hradec Kralove-University Hospital Hradec Kralove Hradec Králové, Czechia

University Hospital Olomouc Olomouc, Czechia

University Hospital Ostrava Ostrava, Czechia

University Hospital Ostrava Ostrava, Czechia

View all 24 locations

View Trial Details

Paraproteinemias

Paraproteinemias trial results

Related conditions